Previous 10 | Next 10 |
2024-05-01 17:20:55 ET More on Castle Biosciences Castle Biosciences, Inc. (CSTL) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Castle Biosciences Historical earnings data for Castle Biosciences Financial information for Castle Biosc...
The Company is proud to collaborate on a number of additional initiatives during the month of May Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and init...
2024-04-20 14:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2024, after the close of market on Thursday, May 2, 2024. Company management w...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, recognizes the importance of Esophageal Cancer Awareness Month and is providing its support of key programs and initiatives throughout the month of April. The Company is proud to ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that, for the second year in a row, its chief financial officer, Frank Stokes, has been selected as a Top 25 CFO of Houston by TOP CFOs (formerly Finance & Inv...
If choosing to use a molecular test to rule-out a sentinel lymph node biopsy (SLNB) in patients diagnosed with melanoma, it is important to show that patients foregoing an SLNB have low risk outcomes; Castle’s poster on DecisionDx-Melanoma shows that patients foregoing an SLNB due to a Dec...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, Apri...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Rodney Cotton has been appointed to its board of directors, effective immediately, and will stand for election at Castle’s 2024 Annual Meeting of Stock...
Company honored for creating an exceptional, people-first culture that empowers employees and fosters trust, transparency and authenticity Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has re...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NYSE Market:
Castle Biosciences Inc. Website:
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...
Castle’s TissueCypher test has been shown to improve the risk stratification of patients with Barrett’s esophagus (BE) 1,2 Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the lat...